Zhi-Qiang Wang

Zhi-Qiang Wang

Auto-generated profile, based on publicly available information

Zhi-Qiang Wang

Department of General Surgery, Shanghai Tongren Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200336, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in Experimental Cell Research
Verified
Journal Article
Closed access
ZWZhiqiang Wang
Zhiqiang Wang
PSPeng Sun
Peng Sun
CGChun Gao
Chun Gao
JCJi Chen
Ji Chen
JLJun Li
Jun Li
JXJiang Xie
Jiang Xie

19 November 2020 in Gastroenterology Research and Practice
Verified
Journal Article
Open access
PDF file
RZRui-zhe Zheng
Rui-zhe Zheng
JXJiang Xie
Jiang Xie
SZShui-Qiang Zhang
Shui-Qiang Zhang
WLWen Li
Wen Li
BDBo Dong
Bo Dong
ZWZhi-Qiang Wang
Zhi-Qiang Wang
Background and Aims. Cancer-specific survival (CSS) of rectal cancer (RC) is associated with several factors. We aimed to build an efficient competing-risk nomogram based on log odds of positive lymph nodes (LODDS) to predict RC survival. Methods. Medical records of 8754 patients were collected from the Surveillance, Epidemiology, and End Results (SEER) database, of 4895 patients from SEER during 20112014 and of 478 patients from an Eastern center as a development cohort, validation cohort, and test cohort, respectively. Univariate and multivariate competing-risk analyses were performed to build competing-risk nomogram for predicting the CSS of RC patients. Prediction efficacy was evaluated and compared with reference to the 8th TNM classification using the factor areas under the receiver operating characteristic curve (AUC) and Brier score. Results. The competing-risk nomogram was based on 6 variables: size, M stage, LODDS, T stage, grade, and age. The competing-risk nomogram showed a higher AUC value in predicting the 5-year death rate due to RC than the 8th TNM stage in the development cohort (0.81 vs. 0.76), validation cohort (0.85 vs. 0.82), and test cohort (0.71 vs. 0.66). The competing-risk nomogram also showed a higher Brier score in predicting the 5-year death rate due to RC than the 8th TNM stage in the development cohort (0.120 vs. 0.127), validation cohort (0.123 vs. 0.128), and test cohort (0.202 vs. 0.226). Conclusion. We developed and validated a competing-risk nomogram for RC death, which could provide the probability of survival averting competing risk to facilitate clinical decision-making.